MSF. The prestigious medical journal The Lancet published the results of a new vaccine against Ebola, named VSV-ZEBOV, indicating a 100 percent effective ten days after being given to a person who was not infected. In the trial involved 4,000 people have been in close contact with hemorrhagic virus in Guinea, one of the three countries affected by the current epidemic.
Due to the urgency required by this crisis, the clinical development of this vaccine is made from the initial human trial to demonstrate the efficacy and safety of the vaccine in a Phase III study in Guinea within 12 months, record time. A great team that included scientists, doctors, epidemiologists and experts from the World Health Organization (WHO), Norway, Canada, Guinea, MSF, universities in Florida, Maryland and Bern, and said mounted London School of Hygiene & amp; Tropical Medicine.
Funding was obtained from the Wellcome Trust, Norway, Canada, WHO and Doctors Without Borders.
No comments:
Post a Comment